Symbols

PVLA

Palvella·NASDAQ

--(--)

PVLA fundamentals

PVLA Q4 2025 Earnings Preview

Palvella (PVLA) expects to report earnings on Mar 31, 2026, with estimated revenue of 0 (YoY --), and EPS at -0.9112 (YoY --).

Revenue estimate / YoY

EPS estimate / YoY

-0.9112

Report date

Mar 31, 2026

PVLA Earnings Call Summary for Q4,2025

Breakthrough Pipeline Momentum: Phase II CVM data exceed expectations, Phase III SELVA study enrollment surpasses targets, and $230M financing secures 2027 FDA approval path.
Commercial Readiness: 20-40 sales rep hiring, patient services hub, and $100K-$200K pricing for MLM launch.
Financial Strength: $274M cash runway supports all programs, with 2026 cash burn of ~$80M.
FDA Alignment: Single-arm Phase III design for MLM validated, 98% patient retention in Phase III SELVA study.
Pipeline Expansion: QTORIN platform expands to 6 diseases, with Phase II DSAP and angiokeratoma studies in 2026.

Earnings

EPS

Revenue

Revenue & Expenses

Key Indicators

Palvella (PVLA) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

Palvella (PVLA)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.

Trend

Breakdown

Balance Sheet

Palvella (PVLA)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.

Trend

Breakdown

Cash Flow

Palvella (PVLA)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.

Trend

Breakdown